ArticleMultiple sclerosis and related disorders2020
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Article in Multiple sclerosis and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.Multiple sclerosis and related disorders · 2021Pooled it
- Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?Current opinion in psychiatry · 2021Pooled it
- Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action.Inflammopharmacology · 2022Review
- Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.Current neuropharmacology · 2022Article
- The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders.Biochemical pharmacology · 2022Review
- Multiple Sclerosis, COVID-19 and Vaccines: Making the Point.Neurology and therapy · 2021Review
- SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.Human vaccines & immunotherapeutics · 2021Article
- Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.Journal of neurology · 2021Article
- Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown.European journal of neurology · 2021Review
- Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.Multiple sclerosis and related disorders · 2021Article
- Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.Vaccines · 2021Review
- SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.Neurology(R) neuroimmunology & neuroinflammation · 2021Observational
- Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?Journal of medical virology · 2021Article
- Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients.Journal of medical virology · 2021Review
- Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.ImmunoTargets and therapy · 2021Review
- Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/
resultsWe describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae.
conclusionIn selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.